Yazar "Ayhan, Erkan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    The association between coronary slow flow and platelet distribution width among patients with stable angina pectoris
    (Termedia Publishing House Ltd, 2014) Ozyurtlu, Ferhat; Yavuz, Veysel; Cetin, Nurullah; Acet, Halit; Ayhan, Erkan; Isik, Turgay
    Introduction: Coronary slow flow (CSF) is an angiographic phenomenon characterised by the delay of distal vessel opacification in the absence of significant stenosis of the epicardial coronary arteries. Some of the factors playing a role in CSF pathophysiology are increased thrombogenic activity and inflammation. Aim: To examine the relationship between platelet distribution width (PDW) and CSF. Material and methods: Taking into consideration the exclusion criteria, 136 patients with CSF and 152 patients with normal coronary angiographies (control group) were included in the study. The association between thrombolysis infarction frame count (TFC) in myocardial and laboratory and other clinical parameters were evaluated. Results: The stated parameters were significantly higher in the group with CSF than in the normal coronary angiography group (control group). The PDW (16.6 +/- 0.7 vs. 16.4 +/- 0.6, p = 0.002), neutrophil lymphocyte ratio (NLR) (3.1 +/- 3.4 vs. 2.4 +/- 1.1, p = 0.027), haemoglobin (Hb) (14.1 +/- 1.3 vs. 14.7 +/- 1.1, p < 0.001), and red cell distribution width (Row) (13.6 +/- 0.7 vs. 14.1 +/- 2.8, p = 0.026) were significantly higher in the CSF group than in the control group. Moreover, our study showed that PDW > 16.15 and Hb > 13.75 were predictors of the presence of CSF with sensitivities of 83% and 73% and specificities of 40% and 42%, respectively. Conclusions: This study has demonstrated that compared to normal coronary flow, PDW, Hb, NLR, and RDW are significantly higher in CSF patients. We believe that further studies are needed to clarify the role of PDW and Hb in patients with CSF.
  • Küçük Resim
    Öğe
    An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design
    (Türk Kardiyoloji Derneği, 2015) Ertaş, Faruk; Kaya, Hasan; Yıldız, Abdulkadir; Davutoğlu, Vedat; Kiriş, Abdulkadir; Dinç, Lale; Kafes, Habibe; Avcı, Anıl; Çalapkorur, Bekir; Ertaş, Gökhan; Gül, Mehmet; Ay, Nuray Kahraman; Bulur, Serkan; Durukan, Mine; Eren, Murat; İlhan, İbrahim; Küçük, Murathan; Özpelit, Ebru; Şimşek, Hakkı; Uçar, F. Mehmet; Yıldız, Ahmet; Şahin, Yıldıray; Ayhan, Erkan; Çağlayan, Emre; Güngör, Hasan; Özyurtlu, Ferhat; Şen, Nihat; Vatan, Bülent; Vatansever, Fahriye; Kobat, Mehmet Ali; Temiz, Ahmet; Taylan, Gökay; Dönmez, İbrahim; Erkuş, M. Emre; Söylemez, Selami; Zengin, Halit; Gündüz, Mahmut; Tuncez, Abdullah; Karavelioğlu, Yusuf; Gökdeniz, Tayyar; Koza, Yavuzer; Aktop, Ziyaeddin; Katlandur, Hüseyin; Özer, Pelin Karaca; Yüksel, Murat; Acet, Halit; Çil, Habib; Alan, Sait; Toprak, Nizamettin
    Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).
  • [ X ]
    Öğe
    Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults
    (Springer-Verlag Italia Srl, 2013) Onat, Altan; Can, Gunay; Cicek, Gokhan; Ayhan, Erkan; Dogan, Yuksel; Kaya, Hasan
    We determined in non-diabetic persons the risk of fasting and non-fasting glucose levels for pre-diabetes, diabetes, and coronary heart disease (CHD), including the roles of serum C-reactive protein (CRP) and HDL cholesterol, and delineated risk profiles of the pre-diabetic states. Over 7A1/4A years, 2,619 middle-aged Turkish adults free of diabetes and CHD were studied prospectively. Using different serum glucose categories including impaired fasting glucose (IFG, 6.1-6.97 mmol/L) and impaired glucose tolerance (IGT), outcomes were analyzed by Cox regression. IFG was identified at baseline in 112 and IGT in 33 participants. Metabolic syndrome components distinguished individuals with IFG from those with normoglycemia. Participants with IGT tended to differ from adults in normal postprandial glucose categories in regard to high levels of triglycerides, apoA-I, and CRP. Diabetes risk, adjusted for sex, age, waist circumference, CRP, and HDL cholesterol, commenced at a fasting 5.6-6.1 mmol/L threshold, was fourfold at levels 6.1-6.97 mmol/L. Optimal glucose values regarding CHD risk were 5.0-6.1 mmol/L. Fasting and postprandial glucose values were not related to CHD risk in men; IGT alone predicted risk in women (HR 3.74 [1.16;12.0]), independent of age, systolic blood pressure, non-HDL cholesterol, waist circumference, smoking status, and CRP. HDL cholesterol was unrelated to the development of IFG, IGT, and diabetes, while CRP elevation independently predicted the development of diabetes. IGT independently predicts CHD risk, especially in women. HDL dysfunction associated with low-grade inflammation is a co-determinant of pre-diabetic states and their progression to diabetes.